Comparative risk assessment of tobacco smoke constituents using the margin of exposure approach: the neglected contribution of nicotine by Lachenmeier, Dirk et al.
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Tobacco smoking can cause numerous diseases such as cardiovascular disease, chronic obstructive pulmonary 
disease and various types of cancer including lung, oral, esophageal and bladder cancer1. Tobacco smoking has 
been classified as “carcinogenic to humans” (group 1) by the International Agency for Research on Cancer2. The 
World Health Organization (WHO) forecasts that cigarettes will kill nearly 10 million people per year globally 
by the year 20202, and the reduction of smoking is crucial to achieve the goals of the “Global Action Plan for 
Prevention and Control of Non-Communicable Diseases (NCDs)”3,4.
Tobacco smoke is a complex chemical mixture containing more than 5000 components2,5–10. Classes of com-
pounds include but are not limited to neutral gases, carbon and nitrogen oxides, amides, imides, lactames, car-
boxylic acids, lactones, esters, aldehydes, ketones, alcohols, phenols, amines, N-nitrosamines, N-heterocyclics, 
aliphatic hydrocarbons, monocyclic and polycyclic aromatic hydrocarbons, nitriles, anhydrides, carbohydrates, 
ethers, nitro compounds and metals2,7,8,11. The available knowledge on the relationship between tobacco smoking 
and the development of cancer in humans is based primarily on epidemiological evidence. A large amount of 
such evidence has become available over the last decades2. More than 70 carcinogens in tobacco smoke have been 
evaluated by the IARC monographs programme, and sixteen of these are classified as carcinogenic to humans 
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into group 12. Nicotine was not among the evaluated substances. Although nicotine is most commonly not con-
sidered as being carcinogenic itself, the risk of long-term nicotine intake is more or less unknown and under 
researched12. Some limited research shows that nicotine can stimulate the growth of lung cancer cells and may 
contribute to apoptosis12. Nevertheless, nicotine is currently not considered as a tobacco smoke constituent that 
is recommended by WHO for lowering13.
In the past, several studies provided lists of hazardous compounds in tobacco smoke. The various lists differ in 
composition of focused toxicants. The most established list is the so-called Hoffmann-list from the 1990s, which 
only includes carcinogens5. Most risk assessment studies are based on this Hoffmann list. This may be the reason 
why nicotine has been neglected.
There is significant evidence, that nicotine is the primary psychoactive component of tobacco smoke. Nicotine 
dependence, as defined by the International Classification of Diseases (ICD), is a chronic brain disorder, resulting 
from the interaction of several factors, and includes physical, psychological and social characteristics (for reviews 
see: refs 14–16).
Nicotine addictive effects are mediated through the binding to nicotinic acetylcholine receptor (nAChR) sub-
types expressed in the brain, particularly located on dopaminergic neurons in the ventral tegmental area and 
stimulating the release of dopamine in the shell of the nucleus accumbens, which is the important mechanism in 
drug-induced reward (“brain’s reward system”)17–19. Additionally, changes in the dopamine level are supported 
by nicotine-induced release of other neurotransmitters, e.g. nicotine also augments glutamate release (which 
facilitates the release of dopamine) and γ -aminobutyric acid (GABA) release (which inhibits dopamine release) 
in these brain areas14,17,18.
The increase in dopamine level in the reward system signals a pleasurable experience. The repeated association 
with smoking-perceived positive effects in combination with a long-lasting conditioning to additional triggering 
stimuli promotes further nicotine consumption16,20. With long-term exposure to nicotine intake neuroadaptation 
(tolerance) develops, the existing nAChRs become less sensitive (desensitization/inactivation), which is accom-
panied by nicotine-induced upregulation of the receptor18,21.
Nicotine is rapidly and extensively (more than 80%10) metabolized by the liver, primarily by the liver enzyme 
CYP2A6 (and to a lesser extent by CYP2B6 and CYP2E1) to cotinine22. Variability in rate of metabolism con-
tributes to vulnerability to tobacco dependence, response to smoking cessation treatment, and lung cancer risk15.
One of the currently most preferred approaches for quantitative risk assessment is the margin of exposure 
(MOE). The margin of exposure (MOE) is the ratio between a defined point on the dose-response curve for the 
adverse effect and the human intake. A suitable point of reference from the dose-response curve is the lower 
confidence limit of the dose which causes a benchmark response of 10% (BMDL10). The magnitude of the risk 
is reciprocally proportional to the MOE. In general for carcinogens an MOE of 10,000 or higher would be of low 
concern from a public health point of view and might be considered as a low priority for risk management. The 
more the MOE falls below 10,000, the higher is the risk of the substance for the considered toxicological endpoint.
Cunningham et al.9 presented a risk assessment of numerous tobacco smoke toxicants based on the MOE 
approach. For this, available toxicological data from the literature was used to calculate the BMDL10 and finally 
the MOE for each component with the objective to segregate the toxicants. A similar study from Xie et al.23 made 
a probabilistic risk assessment approach to prioritize the chemical constituents in mainstream smoke of ciga-
rettes. For this purpose the MOE model was used as well. However both of the surveys did not include nicotine 
in the assessment.
Only a few previous studies researched the margin of exposure of nicotine but did not include the other 
tobacco toxicants. Lachenmeier and Rehm24 conducted a comparative risk assessment of drugs including alcohol 
and tobacco, the MOE of nicotine in tobacco being in the high risk category. Hahn et al.25 researched and assessed 
electronic cigarettes concerning chemical composition and exposure estimation based on the MOE approach. In 
this case, nicotine was the compound with the highest risk.
The intention of this study is therefore to provide a holistic comparative risk assessment of all tobacco and 
tobacco smoke components–for the first time including nicotine–using the MOE approach.

A summary of toxicological thresholds for various effects of nicotine is shown in Table 1. Literature data was used 
to determine the BMDL values for each effect (See data appendix provided as Supplementary Material for raw 
results of benchmark dose-response modelling). The values of BMDL10 depend on the researched toxic effect and 
range from 0.004 mg/kg bodyweight (bw) for various symptoms of intoxication (human (children)) and 0.2 mg/
kg bw for toxic effects in the liver (rats) up to 3 mg/kg bw for mortality (various animal species, probabilistic cal-
culation based on data from bird, dog, mouse and rat, see Lachenmeier and Rehm24 for details).
Based on the data from Cunningham et al.9, Xie et al.23 and own data (Lachenmeier and Rehm24), nicotine 
exposure from smoking cigarettes was calculated (Table 2).
As no information about the most likely function for intake distribution is available, a uniform probability 
distribution was entered into the calculation in this case (Supplementary Tables S1 and S2). The calculated mean 
values of daily nicotine intake range from 0.229 mg/kg bw/day up to 0.543 mg/kg bw/day.
The margins of exposure for tobacco smoke constituents including nicotine are given in Table 3. The MOEs of 
the smoke constituents (except nicotine) are extracted from Xie et al.23 and Cunningham et al.9. For the toxicants 
that had several different MOEs tabulated for various endpoints, the lowest MOE was used in each case. Generally 
only toxicants with MOE below 10,000 were considered. The data for nicotine were calculated in this study based 
on the exposure data from Xie et al.23 and Cunningham et al.9, as well as our own data. The lowest MOE values of 
smoke toxicants based on the methodology of Xie et al.23 are in the range between 15 and 18 (hydrogen cyanide, 
1,3-butadiene, acrolein). According to the methodology of Cunningham et al.9, the substances in tobacco smoke 
with the highest toxicological risks are acrolein, formaldehyde and cadmium compounds (mean MOE 1–8). 
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Nicotine indicates even a higher potential toxicological risk; for four different toxicological endpoints and species, 
the MOEs of nicotine were calculated as ranging from 0.04 up to 7.6 (Fig. 1). The full numerical results of the 
MOE distributions are presented in Supplementary Table S3.
For sensitivity analysis, convergence testing during the probabilistic simulation was conducted. Convergence 
was achieved for all calculated output MOE values. This means that the generated output distributions are stable 
and reliable. The estimated means change less than 5% as additional iterations are run during the simulation. 
From the model input variables, the highest influence (as expressed by rank of regression coefficients) on the 
results is caused by the number of cigarettes per day, with the bodyweight on second position, and only a minor 
influence of nicotine yield per cigarette.
0	
Some studies have performed a cumulative risk assessment on tobacco smoke toxicants by computing a total 
MOE. A total or cumulative MOE can be calculated by building the reciprocal of the sum of the reciprocals of 
the single MOEs. The implementation of this method was not possible in the current study because the toxicants 
have different target organs and effect mechanisms that makes it impossible to estimate a meaningful total MOE 
for tobacco toxicants.
This study allows comparing the potential toxicological risk of several tobacco smoke constituents especially 
in comparison with nicotine by using the MOE approach. For that purpose toxicity data of nicotine has been used 
to estimate the MOE and the results were compared to MOEs of various other tobacco toxicants from the litera-
ture. Due to the fact that adequate toxicity threshold data were unavailable for nicotine, BMDL values had to be 
calculated from literature dose-response data by own modelling. BMDL10 values of nicotine were derived for five 
toxicological endpoints (Table 1). For four of those endpoints the margins of exposure were calculated (Fig. 1). 
All four computed MOE distributions of nicotine are below 10 and may be interpreted as indicating a very high 
risk of this compound for tobacco smokers.
The MOE for the endpoint “heart rate acceleration” is based on data from Lindgren et al.26 who investigated 
the effect of nicotine in humans after i.v. dosage. As this endpoint is the most sensitive effect, the MOE is the low-
est (0.04). However, this may be an overestimation of the risk. The detected heart rate increase of approximately 7 
beats/min was still within the normal range of intraday fluctuations27 and is therefore not necessarily an adverse 
effect. The Lindgren et al.26 data is also statistically questionable for dose-response assessment, because the stand-
ard deviations of the data points were not provided and had to be estimated (see data appendix). In addition, a 
discrepancy exists in the study regarding the exposure units. On the one hand, the unit of nicotine is specified 
in the unit ng/ml plasma. However identical numerical values are mentioned in the results section as being in 
the unit μ g/kg bw, which is not mathematically possible. The corresponding author was not able to clarify the 
discrepancy in the data (Lindgren 2015, personal communication). For these reasons, we believe that the MOE 
data based on Lindgren et al.26 cannot be judged as reliable and should be carefully scrutinized prior to their use 
as the basis for risk management action. It must be mentioned that EFSA28 judged Lindgren et al.26 as a pivotal 
study, which was exclusively used as the basis for EFSA’s risk assessment, the rationale probably being to provide 
the most conservative assessment.
The second considered effect was “addiction” in humans based on data from Benowitz and Henningfield29. 
The derived average MOE is 0.2. This is clearly in the high risk range and biologically plausible as nicotine is 
known as the addictive principle in tobacco29,30. Nevertheless, we are reluctant to use this value for risk assess-
ment, as “addiction” is a rather vague concept which changed its definition remarkably often over the past 50 
years, even if only medical classifications are considered31–33.
Species Effect Type of endpoint Value [mg/kg bw] Reference
Humans, i.v., acute Heart rate acceleration LOAEL 0.008a EFSA28 based on Lindgren et al.26 
Humans, i.v., acute Heart rate acceleration BMDL for BMR = 1SD 0.013
Own modellingc based on data 
from Lindgren et al.26
Humans, chronic cigarette use Addiction Threshold 0.07b Benowitz and Henningfield29 
Humans (Children), dermal, acute Various symptoms of intoxication LOEL 0.01 EFSA28 based on Woolf et al.34
Humans (Children), dermal, acute Various symptoms of intoxication BMDL10 0.004
Own modellingc based on data 
from Woolf et al.34 
Various animal species, acute Mortality (LD50 studies) BMDL10d 3 Lachenmeier and Rehm24
Rats, 10-day study Liver: fatty change BMDL10 0.27
Own modellingc based on data 
from Yuen et al.10 
Rats, 10-day study Liver: focal necrosis BMDL10 0.24
Own modellingc based on data 
from Yuen et al.10 
Rats, 10-day study Liver: dark cell change BMDL10 0.21
Own modellingc based on data 
from Yuen et al.10 
Rats, 10-day study Pathological changes in liver NOAEL 1.25
US EPA61 based on data from 
Yuen et al.10 
Table 1.  Toxicological thresholds of nicotine. aBased on a LOAEL of 0.0035 mg/kg bw using a correction 
factor of 0.44 (extrapolation from the intravenous route to the oral route). For methodology see EFSA28. 
bRecalculated from the threshold level of 5 mg/day29 assuming an average bodyweight of 73.9 kg62. cSee data 
appendix provided as supplementary material for raw results of benchmark dose-response modelling. dThe 
BMDL10 was extrapolated from LD50 data in various animal studies in bird, dog, mouse and rat24.
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The other two endpoints rely on animal bioassays. For the effect “changes in rat liver” (fatty change, focal 
necrosis and dark cell change) an average MOE of about 0.61 was calculated based on data of Yuen et al.10. This 
calculation may, however, underestimate the risk of nicotine due to the very short duration of the liver toxicity 
study of only 10 days.
Finally, according to the severity of the toxicological endpoint, the average MOE of 7.6 for animal mortality 
is the highest (data based on several acute studies on various animal species summarized in Lachenmeier and 
Rehm24).
For the toxicological endpoint “various symptoms of intoxication in children” based on data from Woolf et al.34 
the MOE was not calculated. The authors believe that this acute dermal exposure study in children is not appli-
cable for risk assessment of habitual smoking, because of the different exposure conditions and questionable 
transferability to adults.
With a MOE from below 1 up to 7.6, the risk of nicotine is in the same dimension as the tobacco (smoke) 
toxicants with the lowest MOE such as acrolein, formaldehyde and cadmium compounds, which are the tobacco 
toxicants with the highest concerns relating to adverse health effects. There appears to be a fundamental problem 
that nicotine has never before been included in any risk assessment on tobacco or tobacco smoke toxicants. There 
are numerous studies about toxicological investigations from the tobacco industry and other authors available. 
Those studies tried to identify the most important toxicants from tobacco and to correlate them to the various 
diseases caused by cigarette smoking. However, nicotine has not been evaluated in any of them5,6,13,35,36. Up to 
now nicotine has not been associated with carcinogenesis but the risk of long-term nicotine intake is more or less 
unknown and under-researched12. The correlation of the disease risk to smoking dose, the mode of action and 
the etiology of the disease pathologies are not well understood36. Pankow et al.37 suggested that only about 4% of 
the observed risk for lung cancer can be explained by tobacco smoke toxicants. Also, in this case nicotine has not 
been part of the research. Could nicotine therefore explain a large part of the remaining risk? Currently there is 
only limited evidence to corroborate this hypothesis. Some experimental studies of different laboratories show 
that nicotine might promote or increase the risk of cancer1,12. West et al.12 demonstrated that it can stimulate the 
growth of lung cancer cells and may contribute to apoptosis. In alcohol, it had also been postulated for a long 
time, that ingredients other than ethanol were the main carcinogens, before ethanol itself was found as the main 
causal agent38,39. The correlation between smoking cigarettes and cancer is well established2. However, nicotine 
is so far considered as an addictive substance in tobacco smoke but not as a carcinogen. Bavarva et al.40 investi-
gated the genomic influence of nicotine and its genotoxic mechanism mediated through oxidative stress in a cell 
line experiment. The results indicate that nicotine exposure can adversely affect the human genome by inducing 
somatic mutations and may contribute to increased cancer incidence, characterizing nicotine as a carcinogen or 
mutagen.
In addition to the ones located in the brain, nicotine receptors are found throughout the body; for example, in 
muscle, endothelia, kidney and skin, in normal lung and in lung tumors. These receptors are involved in a number 
of cellular pathways of carcinogenesis. That provides some mechanistic plausibility to the hypothesis that nicotine 
may contribute to the carcinogenic process1. But the studies have limitations in replicating human exposure and 
human evidence is clearly lacking so far. More research is needed to clarify if nicotine may make the major con-
tribution to the mechanistically unexplained adverse effects. For example, there is no study on cancer endpoints 
currently available that would allow to calculate a MOE for this effect. We can only speculate if the pyrolysis prod-
ucts have been a misleading focus for research whereas the actual carcinogen has been neglected. Nicotine has 
previously not been evaluated by IARC but is on the current list of IARC to be re-evaluated with high priority41.
Our research showing that nicotine is among the top risk compounds in tobacco smoke leads to the question 
why there are no nicotine reduced cigarettes available on the market. Possibly the tobacco industry would lose 
clients if the nicotine exposures falls below the threshold of addiction42,43. It is proven that nicotine-reduced 
cigarettes would be less addictive44,45. For example, in a 10 week longitudinal study, the subjects at first smoked 
their usual brand followed by different types of research cigarettes with progressively lower nicotine content, 
each smoked for 1 week. After 4 weeks, 25% of the participants had spontaneously quit smoking46. The results 
of a 6-week research show that nicotine-reduced cigarettes lower its exposure, dependence and the number of 
cigarettes smoked45. These findings suggest that reducing the nicotine content of cigarettes could facilitate to quit 
smoking and therefore increase public health45. In the USA nicotine reduced cigarettes is a topic of major concern 
Study Nicotine content per cigarette Cigarette smoking per day Bodyweight
Calculation 
method
Average daily nicotine 
intake (smokers)
Cunningham et al.9 
Constituent yield from 1R4F 
cigarettes under the Health Canada 
Intense machine-smoke regime 
[note: the 1R4F reference cigarette 
contains 0.8 mg nicotine according to 
Calafat et al.63]
20 cigarettes/day 70 kg64 Point estimate 0.229 mg/kg bw/daya
Xie et al.23
Analyses of 30 brands of 
cigarettes sold in China using the 
Canadian intense smoking regime 
(2.09 ± 0.25 mg nicotine/cigarette)
Data from the 2006 China Health 
and Nutrition survey (average 16.4 
cigarettes/day, P5 3 cigarettes/day, 
P95 30 cigarettes/day)
Average 63.3 kg, P5 
46.7 kg, P95 84.2 kg
Probabilisticb 0.543 mg/kg bw/dayc
Lachenmeier and Rehm24 1.65–1.89 mg nicotine/cigarette47 10–20 cigarettes/day65 73.9 ± 12 kg62 Probabilisticb 0.359 mg/kg bw/day
Table 2.  Data sources applied to calculate exposure for tobacco consumption-related toxicants and 
nicotine. aOwn calculation based on data from Cunningham et al.9. bSee Supplementary Tables S1 and S2 for 
distribution functions and calculation methodology. cOwn calculation based on data from Xie et al.23.
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for research and policy since the commencement of an act in 200942. Low-nicotine cigarettes have been and are 
on the US market43. However, they have not been successfully marketed owing to the issue of how much nicotine 
may be removed without affecting the taste. The tobacco industry did extensive research to determine the thresh-
old of targeting nicotine dosing by cigarettes42. Benowitz and Henningfield29 derived a threshold level of nicotine 
in cigarettes from 5 mg or less to avert addiction. Instead Land et al.47 concluded that the tobacco manufacturers 
even increased the nicotine yield over the years.
In contrast, some studies showed that smoking nicotine reduced cigarettes leads to more intensive smok-
ing to compensate for the necessity of nicotine48–51. For example, Ashton et al.48 suggested that smokers may 
compensate for about two-thirds of the difference in standard yields when switched from medium-nicotine to 
high or low-nicotine brands. The results show evidence of both upward and downward self-titration of nicotine 
intakes by smokers. This was confirmed by Gable52 who concluded that smokers tend to titrate to approximately 
1 mg per cigarette by varying number and duration of puffs. Henningfield49 concluded that there are no health 
benefits on smoking cigarettes with lower (tar and) nicotine levels compared to “normal yields”. Woodward and 
Tunstall-Pedoe51 believe that in the case of deeper inhalation more carcinogenic pyrolysis products would be 
absorbed and concluded that not cigarettes with the lowest nicotine yields but those with low tar, low carbon 
monoxide and high nicotine yields appears to be the “most safe” cigarette. In contrast, Frenk and Dar53 do not 
confirm the “nicotine compensation hypothesis”. They are of the opinion that if nicotine is addictive in the same 
sense that heroin is, smokers would rapidly increase their dose (like heroin-dependent users do) by smoking 
more cigarettes or increasing number of puffs or deeper inhalation of the puffs or switching to cigarettes with a 
higher nicotine yield. But smokers do not. They arrive rapidly at their preferred number of cigarettes per day and 
the number remains stable for years. The conclusion of Frenk and Dar53 is that nicotine seems to be involved in 
a down-regulation mechanism but not in up-regulation. In fact light cigarettes may be smoked more intensely 
because of the sensory reward of their reduced tar and taste.
Study Xie et al.23 Cunningham et al.9
Constituenta Point of departure (species/endpoint) MOE Mean MOE P5 MOE Median MOE P95
Point of departure (species/
endpoint)
MOE Mean
HCN Human/Thyroid 15 4 9 46 not included in study
1,3-Butadiene Human/Leukaemia 18 4 10 52
Mice/Alveolar/bronchiolar 
adenoma and carcinoma
114
Acrolein Rat/Nasal lesions 18 4 11 51
Rats/Laryngeal-epithelial 
squamous metaplasia
1
Acrylonitrile Rat/Nasal histopathology 49 9 25 148
Rat/Flattening of respiratory 
epithelium nasal turbinates
42
Isoprene Mouse/Spleen hemangiosarcoma 58 15 35 173
Mice/Nasal turbinate olfactory 
epithelial degeneration
325
Formaldehyde Rat/Nasal cancer 102 21 59 307 Rats/Nasal squamous metaplasia 8
Acetaldehyde Rat/Nasal tumours 166 42 100 490 Rats/Nasal adenocarcinoma 143
Cadmium compounds Human/Kidney 196 23 65 499 Rats/Any lung tumours 6
Catechol Rat/Glandular stomach hyperplasia 251 58 139 733 not included in study
Benzene Human/Decreased lymphocyte count 552 148 326 1596 not included in study
Chromium Rat/Respiratory 646 157 390 1941 not included in study
Ammonia Rat/Respiratory 1373 289 829 4201 not included in study
Arsenic Human/Lung cancer 1378 265 782 4283 not included in study
Quinoline Rat/Liver tumours 1528 373 920 4537 not included in study
Pyridine Mouse/Liver tumours 1552 391 936 4556 not included in study
Styrene Human/CNS effects 2644 645 1572 7765 not included in study
NNK Rat/Lung Cancer 3038 139 538 5857 Rats/Lung tumours 338
m/p-Cresol Mouse/Nasal lesions 6735 1518 4023 20322 Mice/Lung bronchial hyperplasia 648
Ethylene oxide not included in study
Mice/Alveolar/bronchiolar 
carcinoma or adenoma
2239
NNN Rat/Nasal cavity tumours 263982 9554 37445 470255 Rats/Nasal tumours 3295
The following data for nicotine were calculated in this study based on the exposure data from Xie et al.23 and Cunningham et al.9
Nicotine
Human/Heart rate acceleration 
(BMDL)
0.03 0.01 0.02 0.06
Human/Heart rate acceleration 
(BMDL)
0.06
Nicotine Rats/Liver dark cell change 0.44 0.18 0.37 0.93 Rats/Liver dark cell change 0.92
Nicotine Animals/Mortality 5 1 4 13 Animals/Mortality 11
Table 3.  Margin of exposure for tobacco smoke constituents summarized from the literature with 
comparison to own calculations for nicotine. The data from Xie et al.23 and Cunningham et al.9 are reprinted 
with permission from Elsevier. aOnly constituents with MOE below 10,000 were included from the literature 
studies. For Cunningham et al.9 the lowest MOE was selected for the constituents that had several different 
MOEs tabulated for various endpoints. The literature data were rounded to the nearest whole number in cases 
when decimals were provided.
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Another important aspect which needs to be considered is the fact that a high number of people use tobacco 
replacement or nicotine products over many years without getting cancer54, for instance pharmaceutical nicotine 
products for nicotine replacement therapy (NRT). NRT products such as nasal sprays, gums, tablets, lozenges 
and transdermal patches are marketed for helping people who want to stop smoking. The intended use of NRT 
products is the application for a fixed period of time. Only few users really quit smoking after this recommended 
time of 8–12 weeks. A lot of people do not stop the application after weeks but use these products over years 
some of them in addition to smoking. The US FDA does not have any significant safety concerns if smokers use 
nicotine replacement products in combination with another product or if they do not stop smoking completely 
before beginning to use smoking cessation products. NRTs do not appear to have a meaningful potential for 
abuse or dependence55. On the other hand, it may be difficult to monitor chronic risks such as cancer from 
over-the-counter products such as NRTs, and confounding to the co-consumption of NRT with smoked tobacco 
is difficult to exclude.
If we assume that nicotine alone or in the form of NRTs does not have any chronic effect, there could be more 
factors involved. One of those might be the type of nicotine exposure. The most precise difference in nicotine 
intake is the speed of effect. It takes only a few seconds for high doses of nicotine from a cigarette to reach the 
brain when inhaled. Medicinal products achieve lower levels over a period of minutes for products such as nasal 
spray or oral products and hours for transdermal patches22,56. Another essential point seems to be the complex 
mixture of nicotine and the other tobacco smoke toxicants. This is the exact difference from conventional ciga-
rettes to electronic cigarettes (e-cigarettes) and NRTs. In conventional cigarettes, tobacco leaves are burned and 
nicotine is transferred besides toxic compounds produced during the combustion of tobacco such as carbon 
monoxide and nitrosamines from the solid phase to the aerosol. In e-cigarettes a nicotine solution is heated and 
nicotine is transferred from the liquid phase to the vapor phase. Because the harmful constituents of cigarette 
smoke are absent or significantly reduced in e-cigarette aerosols, smoking e-cigarettes is supposed to be less 
hazardous than smoking conventional cigarettes57,58. Hence, it may be speculated that nicotine and another com-
pound in tobacco smoke may have cumulative effects.
In conclusion, all MOEs of nicotine in this study are less than 10 and within the range of very high risk. Owing 
to the lack of toxicological data particularly relating to cancer30, long term animal bioassay studies for nicotine 
are urgently necessary. In this context all kinds of possible nicotine exposures as well as certain co-exposures 
(tobacco smoke toxicants) and different nicotine concentrations related to a potential threshold of addiction 
need to be considered. The study from Lindgren et al.26 needs to be replicated. There is immediate need of action 
concerning the risk assessment of nicotine.
:	
Toxicity data on nicotine were obtained by a computer-assisted literature search. Searches were carried out in the 
following databases: PubMed, Toxnet and ChemIDplus (U.S. National Library of Medicine, Bethesda, MD), Web 
of Science (Thomson Scientific, Philadelphia, PA), and IPCS/INCHEM (International Programme on Chemical 
Safety/Chemical Safety Information from Intergovernmental Organizations, WHO, Geneva, Switzerland). We 
specifically aimed to identify clinical and epidemiological studies in humans and long-term animal studies that 
would be usable for dose-response modelling.
The methodology for quantitative risk assessment was based on a previous study for risk assessment of 
drugs24. The MOE approach was used for the risk assessment59,60. The MOE is defined as the ratio between the 
lower one-sided confidence limit of the BMD (BMDL) and estimated human intake of the same compound. If the 
BMDL as preferred toxicological threshold for MOE assessment is unavailable, no observed effect levels (NOEL), 
Figure 1. Margin of exposure for nicotine for daily smokers considering different toxicological endpoints 
(The box is determined by the 25th and 75th percentiles. The whiskers are determined by the 5th and 95th 
percentiles. 1st and 99th percentiles are marked by x, while minimum and maximum are marked with dash).
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no observed adverse effect levels (NOAEL) or lowest observed adverse effect levels (LOAEL) may be applied. The 
values were either taken from the literature search, or additionally BMD and BMDL values were calculated using 
the US EPA’s BMDS 2.6 software (available at the US Environmental Protection Agency website: http://www.
epa.gov/ncea/bmds/index.html). The human nicotine intake for smokers of cigarettes was based on literature 
data9,23,24.
The MOE was then calculated using the software package @Risk for Excel Version 5.5.0 (Palisade Corporation, 
Ithaca, NY, USA). Monte Carlo simulations were performed with 10,000 iterations using Latin Hypercube sam-
pling and Mersenne Twister random number generator. Convergence was tested with a tolerance of 5% and 
a confidence level of 95%. The distribution functions and detailed calculation methodology is specified in 
Supplementary Tables S1 and S2.
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     Input Data File: C:/USEPA/BMDS2601/Data/pow_Lindgren_Lindren.(d)   
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        Thu Aug 20 16:52:31 2015 
 ====================================================================  
 
 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the response function is:  
 
 ?
   Y[dose] = control + slope * dose^power 
 
 
   Dependent variable = Max_beats_per_min 
   Independent variable = Dose 
   rho is set to 0 
   The power is restricted to be greater than or equal to 1 
   A constant variance model is fit 
 
   Total number of dose groups = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 500 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
                  Default Initial Parameter Values   
                          alpha =          100 
                            rho =            0   Specified 
                        control =           63 
                          slope =       290.43 
                          power =        -9999 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -rho    -power    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
                  alpha      control        slope 
 
     alpha            1    -8.1e-009    -8.1e-009 
 
   control    -8.1e-009            1        -0.73 
 
     slope    -8.1e-009        -0.73            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald Confidence 
Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper 
Conf. Limit 
          alpha          93.7721          15.8504              62.706             
124.838 
        control           63.775           1.6872             60.4681             
67.0819 
          slope          535.714          116.916             306.563             
764.866 
          power                1               NA 
 
NA - Indicates that this parameter has hit a bound 
     implied by some inequality constraint and thus 
     has no standard error. 
 
 
 A
 
     Table of Data and Estimated Values of Interest 
 
 Dose       N    Obs Mean     Est Mean   Obs Std Dev  Est Std Dev   Scaled Res. 
------     ---   --------     --------   -----------  -----------   ---------- 
 
    0    14         63         63.8           10         9.68         -0.299 
0.0035    14         66         65.6           10         9.68          0.135 
0.007    14         67         67.5           10         9.68         -0.203 
0.014    14         73         71.3           10         9.68          0.667 
0.028    14         78         78.8           10         9.68         -0.299 
 
 
 
 Model Descriptions for likelihoods calculated 
 
 
 Model A1:        Yij = Mu(i) + e(ij) 
           Var{e(ij)} = Sigma^2 
 
 Model A2:        Yij = Mu(i) + e(ij) 
           Var{e(ij)} = Sigma(i)^2 
 
 Model A3:        Yij = Mu(i) + e(ij) 
           Var{e(ij)} = Sigma^2 
     Model A3 uses any fixed variance parameters that 
     were specified by the user 
 
 Model  R:         Yi = Mu + e(i) 
            Var{e(i)} = Sigma^2 
 
 
                       Likelihoods of Interest 
 
            Model      Log(likelihood)   # Param's      AIC 
             A1         -193.587177            6     399.174355 
             A2         -193.587177           10     407.174355 
             A3         -193.587177            6     399.174355 
         fitted         -193.930374            3     393.860748 
              R         -203.111216            2     410.222432 
 
 
                   Explanation of Tests   
 
 Test 1:  Do responses and/or variances differ among Dose levels?  
          (A2 vs. R) 
 Test 2:  Are Variances Homogeneous? (A1 vs A2) 
 Test 3:  Are variances adequately modeled? (A2 vs. A3) 
 Test 4:  Does the Model for the Mean Fit? (A3 vs. fitted) 
 (Note:  When rho=0 the results of Test 3 and Test 2 will be the same.) 
 
                     Tests of Interest     
 
   Test    -2*log(Likelihood Ratio)  Test df        p-value     
 
   Test 1              19.0481          8          0.0146 
   Test 2         5.68434e-014          4               1 
   Test 3         5.68434e-014          4               1 
   Test 4             0.686393          3          0.8764 
 
The p-value for Test 1 is less than .05.  There appears to be a 
 
difference between response and/or variances among the dose levels 
It seems appropriate to model the data 
 
The p-value for Test 2 is greater than .1.  A homogeneous variance  
model appears to be appropriate here 
 
 
The p-value for Test 3 is greater than .1.  The modeled variance appears  
 to be appropriate here 
 
The p-value for Test 4 is greater than .1.  The model chosen seems  
to adequately describe the data 
  
 
               Benchmark Dose Computation 
 
Specified effect =             1 
 
Risk Type        =     Estimated standard deviations from the control mean  
 
Confidence level =          0.95 
 
             BMD = 0.0180761      
 
 
            BMDL = 0.0130478      
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====================================================================  
      Multistage Model. (Version: 3.4;  Date: 05/02/2014)  
     Input Data File: C:/USEPA/BMDS2601/Data/msc_Woolf_Woolf.(d)   
     Gnuplot Plotting File:  
C:/USEPA/BMDS2601/Data/msc_Woolf_Woolf.plt 
        Thu Aug 20 15:38:26 2015 
 ====================================================================  
 
 BMDS_Model_Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background + (1-background)*[1-EXP( 
                 -beta1*dose^1-beta2*dose^2)] 
 
   The parameter betas are restricted to be positive 
 
 
   Dependent variable = Perc 
   Independent variable = Dose 
 G
 
 Total number of observations = 3 
 Total number of records with missing values = 0 
 Total number of parameters in model = 3 
 Total number of specified parameters = 0 
 Degree of polynomial = 2 
 
 
 Maximum number of iterations = 500 
 Relative Function Convergence has been set to: 1e-008 
 Parameter Convergence has been set to: 1e-008 
 
 
 
                  Default Initial Parameter Values   
                     Background =            0 
                        Beta(1) =            0 
                        Beta(2) = 4.07602e+020 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -Beta(1)    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             Background      Beta(2) 
 
Background            1        -0.33 
 
   Beta(2)        -0.33            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald 
Confidence Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   
Upper Conf. Limit 
     Background         0.287085         0.172829          -0.0516538            
0.625824 
        Beta(1)                0               NA 
        Beta(2)          36.5969          73.4008            -107.266              
180.46 
 
NA - Indicates that this parameter has hit a bound 
     implied by some inequality constraint and thus 
     has no standard error. 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-
value 
     Full model        -5.60136         3 
   Fitted model        -5.60168         2   0.000640384      1          
0.9798 
 
  Reduced model        -8.96765         1       6.73259      2         
0.03452 
 
           AIC:         15.2034 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  -----------------------------------------------------------------------
- 
    0.5000     0.9999         4.000     4.000       4.000        0.017 
    0.0990     0.5020         1.004     1.000       2.000       -0.006 
    0.0100     0.2897         2.028     2.030       7.000        0.002 
 
 Chi^2 = 0.00      d.f. = 1        P-value = 0.9853 
 
 
   Benchmark Dose Computation 
 
Specified effect =            0.1 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =      0.0536558 
 
            BMDL =     0.00399136 
 
            BMDU =       0.173017 
 
Taken together, (0.00399136, 0.173017) is a 90     % two-sided confidence 
interval for the BMD 
 
Cancer Slope Factor =       25.0541
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 ====================================================================  
      Logistic Model. (Version: 2.14; Date: 2/28/2013)  
     Input Data File: C:/USEPA/BMDS250/Data/lnl_Nicotine Yuen et al. 
1995_Nicotine Yuen et al. 1995.(d)   
     Gnuplot Plotting File:  C:/USEPA/BMDS250/Data/lnl_Nicotine Yuen et al. 
1995_Nicotine Yuen et al. 1995.plt 
        Thu Feb 05 09:51:37 2015 
 ====================================================================  
 
 BMDS_Model_Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background+(1-background)/[1+EXP(-intercept-slope*Log(dose))] 
 
 
 
   Dependent variable = FattyChange 
   Independent variable = Dose 
   Slope parameter is restricted as slope >= 1 
 
   Total number of observations = 3 
   Total number of records with missing values = 0 
   Maximum number of iterations = 500 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
   User has chosen the log transformed model 
 
 
                  Default Initial Parameter Values   
                     background =     0.333333 
                      intercept =     -1.03625 
                          slope =      4.64386 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -slope    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             background    intercept 
 
background            1        -0.45 
 
 intercept        -0.45            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald Confidence 
Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper 
Conf. Limit 
     background         0.333332            *                *                  
* 
      intercept         -4.01656            *                *                  
* 
          slope               18            *                *                  
* 
 
* - Indicates that this value is not calculated. 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model        -15.2763         3 
   Fitted model        -15.2764         2  6.10343e-005      1          0.9938 
  Reduced model        -22.9145         1       15.2763      2       0.0004817 
 
 =
           AIC:         34.5527 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.3333         4.000     4.000          12        0.000 
    1.2500     0.6667         8.000     8.000          12       -0.000 
    2.5000     1.0000        12.000    12.000          12        0.006 
 
 Chi^2 = 0.00      d.f. = 1        P-value = 0.9956 
 
 
   Benchmark Dose Computation 
 
Specified effect =            0.1 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =        1.10636 
 
            BMDL =       0.273501 

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 ====================================================================  
      Logistic Model. (Version: 2.14; Date: 2/28/2013)  
     Input Data File: C:/USEPA/BMDS250/Data/lnl_Nicotine Yuen et al. 
1995_Nicotine Yuen et al. 1995.(d)   
     Gnuplot Plotting File:  C:/USEPA/BMDS250/Data/lnl_Nicotine Yuen et al. 
1995_Nicotine Yuen et al. 1995.plt 
        Thu Feb 05 09:55:31 2015 
 ====================================================================  
 
 BMDS_Model_Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background+(1-background)/[1+EXP(-intercept-slope*Log(dose))] 
 
 
   Dependent variable = FocalNecrosis 
   Independent variable = Dose 
   Slope parameter is restricted as slope >= 1 
 
   Total number of observations = 3 
   Total number of records with missing values = 0 
 ?
   Maximum number of iterations = 500 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
   User has chosen the log transformed model 
 
 
                  Default Initial Parameter Values   
                     background =         0.25 
                      intercept =    -0.741267 
                          slope =      4.32193 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -slope    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             background    intercept 
 
background            1        -0.38 
 
 intercept        -0.38            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald Confidence 
Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper 
Conf. Limit 
     background             0.25            *                *                  
* 
      intercept         -3.79342            *                *                  
* 
          slope               18            *                *                  
* 
 
* - Indicates that this value is not calculated. 
 
 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model        -14.3862         3 
   Fitted model        -14.3862         2  5.49311e-005      1          0.9941 
  Reduced model         -23.546         1       18.3196      2       0.0001052 
 
           AIC:         32.7724 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
 A
    0.0000     0.2500         3.000     3.000          12        0.000 
    1.2500     0.6667         8.000     8.000          12       -0.000 
    2.5000     1.0000        12.000    12.000          12        0.005 
 
 Chi^2 = 0.00      d.f. = 1        P-value = 0.9958 
 
 
   Benchmark Dose Computation 
 
Specified effect =            0.1 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =        1.09273 
 
            BMDL =       0.241143 
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 ====================================================================  
      Multistage Model. (Version: 3.4;  Date: 05/02/2014)  
     Input Data File: C:/USEPA/BMDS250/Data/msc_Nicotine Yuen et al. 
1995_Nicotine Yuen et al. 1995.(d)   
 
     Gnuplot Plotting File:  C:/USEPA/BMDS250/Data/msc_Nicotine Yuen et al. 
1995_Nicotine Yuen et al. 1995.plt 
        Thu Feb 05 10:05:08 2015 
 ====================================================================  
 
 BMDS_Model_Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background + (1-background)*[1-EXP( 
                 -beta1*dose^1-beta2*dose^2)] 
 
   The parameter betas are restricted to be positive 
 
 
   Dependent variable = Darkcellchange 
   Independent variable = Dose 
 
 Total number of observations = 3 
 Total number of records with missing values = 0 
 Total number of parameters in model = 3 
 Total number of specified parameters = 0 
 Degree of polynomial = 2 
 
 
 Maximum number of iterations = 500 
 Relative Function Convergence has been set to: 1e-008 
 Parameter Convergence has been set to: 1e-008 
 
 
 
                  Default Initial Parameter Values   
                     Background =     0.084713 
                        Beta(1) =            0 
                        Beta(2) =       0.3728 
 
 
           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -Beta(1)    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             Background      Beta(2) 
 
Background            1        -0.47 
 
   Beta(2)        -0.47            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald Confidence 
Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper 
Conf. Limit 
     Background         0.203839            *                *                  
* 
 
        Beta(1)                0            *                *                  
* 
        Beta(2)          0.26957            *                *                  
* 
 
* - Indicates that this value is not calculated. 
 
                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model        -17.8282         3 
   Fitted model        -18.6431         2       1.62984      1          0.2017 
  Reduced model        -24.9533         1       14.2501      2       0.0008047 
 
           AIC:         41.2863 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    0.0000     0.2038         2.446     3.000      12.000        0.397 
    1.2500     0.4775         5.730     4.000      12.000       -1.000 
    2.5000     0.8523        10.228    11.000      12.000        0.628 
 
 Chi^2 = 1.55      d.f. = 1        P-value = 0.2128 
 
 
   Benchmark Dose Computation 
 
Specified effect =            0.1 
Risk Type        =      Extra risk  
Confidence level =           0.95 
             BMD =       0.625177 
            BMDL =       0.213503 
            BMDU =       0.908647 
Taken together, (0.213503, 0.908647) is a 90     % two-sided confidence 
interval for the BMD 
 
Cancer Slope Factor =      0.468378 


